Shah Capital, the largest shareholder of Novavax, today commented on yesterday’s announced voting results from Novavax’s June ...

Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

Shah Capital, the largest shareholder of Novavax (NVAX), criticized the company’s leadership on Wednesday, even after the ...

Shah Capital, the largest shareholder of Novavax, criticized the company’s leadership after nearly half of votes cast at the ...

Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 11.3% in the afternoon session after documents revealed ...

Novavax's vaccine didn't enter the market until after the inoculations developed by Moderna and Pfizer had already taken dominant market shares. This meant it missed out on the biggest revenue ...

An update from Novavax ( (NVAX)) is now available. At its June 18, 2026 annual meeting, Novavax stockholders elected Class I directors John C. Jacobs, Gregg H. Alton and Richard J. Rodgers to ...

Novavax was close to going under. In early 2023, it warned investors that it might not have enough funds to finish the year. However, the biotech has made significant changes over the past 18 months.

Pharmaceutical Executive: How are new vaccine technologies impacting the vaccine space? Sylvia Taylor: Vaccine technologies ...

Shares of Novavax jumped as much as 50% as Wall Street cheered a new multibillion-dollar deal with French drugmaker Sanofi that kicked off a dramatic turnaround for the struggling vaccine maker.

Novavax's stock almost doubled on Friday after it announced the licensing agreement with Sanofi. Novavax on Friday said the deal allows the company to remove its "going concern" warning, which it ...